Palopegteriparatide

Palopegteriparatide is teriparatide bound to a 20 kDa methoxy-PEG carrier through a linker that hydrolyses at a predictable, pH-dependent rate. The conjugate itself is inactive; as the linker cleaves, free unmodified PTH(1-34) is released continuously over roughly a day, giving a flat exposure profile with an effective half-life of about 60 hours at steady state. This is the deliberate opposite of teriparatide's use in osteoporosis: hypoparathyroidism needs continuous replacement to maintain serum calcium, renal calcium reabsorption and 1,25-dihydroxyvitamin D production, not intermittent anabolic spikes. In the PaTHway phase 3 trial the large majority of patients achieved normal serum calcium while coming off active vitamin D and therapeutic-dose calcium entirely.

Targets: PTH1 receptor, Renal calcium reabsorption, Renal 1-alpha-hydroxylase, Urinary phosphate excretion

• · Start 18 mcg once daily and adjust in 3 mcg steps on albumin-corrected serum calcium. Licensed range is 6 to 30 mcg. Only one injection per dose; splitting across two pens makes the delivered dose unreliable.

Work out your exact syringe units →

• commonHypercalcaemia during titration— Usually from failing to taper calcitriol and calcium fast enough as the dose goes up.
• commonHypocalcaemia— Occurs with missed doses or over-rapid supplement withdrawal.
• commonHeadache
• commonInjection-site reactions
• commonParaesthesia and muscle spasm— Typically a hypocalcaemia signal rather than a direct drug effect.

• Hypersensitivity to PTH products
• Caution with concurrent digoxin, where calcium swings alter toxicity risk
• Not established in paediatric patients with open epiphyses

• redundantpth-1-84 — Both are PTH replacement for hypoparathyroidism; palopegteriparatide has effectively replaced Natpara in the US.
• redundantteriparatide — Same peptide, opposite pharmacokinetic intent.

• · Albumin-corrected serum calcium before dosing at each titration step, then periodically
• · 24-hour urinary calcium
• · Serum phosphate and magnesium
• · Renal function and, over years, renal imaging for nephrocalcinosis

Prescription drug approved in the US and EU for chronic hypoparathyroidism in adults.

• Yorvipath FDA prescribing information (label)
• Khan et al. 2022, PaTHway phase 3 trial of TransCon PTH in adults with hypoparathyroidism (trial)

This is the clearest demonstration in endocrinology that a peptide's clinical identity is set by its kinetics rather than its sequence. The peptide released is teriparatide, atom for atom. Delivered as a daily spike it is an osteoanabolic drug for osteoporosis. Delivered as a flat 24-hour infusion-equivalent it is hormone replacement for hypoparathyroidism, and the two indications have almost nothing in common. The TransCon linker is not enzymatically cleaved, which matters: hydrolysis rate is governed by pH and temperature, so release is predictable across patients and does not depend on variable enzyme expression. The effective half-life of released PTH is about 60 hours, which is why a once-daily injection produces a genuinely continuous profile rather than a sawtooth, and why steady state takes about a week. Physiologically, continuous PTH1R occupancy in the distal nephron restores calcium reabsorption so that normal serum calcium is achieved without the high filtered load that conventional calcium and calcitriol therapy creates. That is the real point of the drug and the reason it is not just an expensive way to raise calcium: patients on calcium and calcitriol are normocalcaemic at the cost of chronic hypercalciuria, nephrocalcinosis and progressive renal impairment, and PTH replacement fixes the urinary calcium as well as the serum calcium. It also restores renal 1-alpha-hydroxylase activity, so endogenous 1,25-dihydroxyvitamin D production resumes and active vitamin D supplements become unnecessary, and it restores phosphaturia, correcting the hyperphosphataemia these patients live with.

Titration errors dominate. Increasing the palopegteriparatide dose while the patient is still on full-dose calcitriol produces hypercalcaemia within days, and the fix is almost always to cut the calcitriol rather than the drug. In the other direction, tapering calcium too aggressively produces paraesthesia, cramps and the tetany these patients dread, which destroys confidence in the therapy. Missed doses matter more than they would with a daily peptide, because the 60-hour effective half-life means a missed dose leaves a real gap and hypocalcaemia can follow. Stopping abruptly is genuinely dangerous: severe hypocalcaemia follows unless calcium and active vitamin D are reinstated first, which is exactly the transition thousands of Natpara patients had to make in 2024. The pen mixes lyophilised drug with diluent inside the device and must not be reconstituted externally. And there is a supply reality worth naming: this is an expensive orphan drug in a category that has already had one product withdrawn for manufacturing failure, so continuity of supply is a legitimate consideration.

1. 18 mcgDay 1 — 18 mcg subcutaneously once daily. On the same day, halve the active vitamin D dose if albumin-corrected calcium is above 7.5 mg/dL, and reduce calcium supplementation. Under-anticipating that step is the main cause of early hypercalcaemia.
2. 21 mcgDays 4-7 and onward — Adjust in 3 mcg increments no more often than every 3 to 7 days, guided by pre-dose albumin-corrected calcium. Withdraw active vitamin D completely before starting to taper supplemental calcium.
3. 30 mcgTitration range — Licensed range is 6 to 30 mcg once daily. Most patients settle somewhere in the middle. Deliver each dose as one injection; splitting across two pens makes the delivered amount unreliable.
4. 6 mcgLower end — 6 mcg is the minimum licensed dose, used in patients with residual parathyroid function or high sensitivity.

• PTH1 receptor in renal distal tubule — Released PTH(1-34) and PTH(1-33) have comparable affinity and activation per the label.

  Continuous stimulation of distal tubular calcium reabsorption, which is what allows normocalcaemia without hypercalciuria.

• PTH1 receptor and renal 1-alpha-hydroxylase — High

  Restores conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D, so calcitriol supplementation can be withdrawn entirely.

• PTH1 receptor in proximal tubule — High

  Reduces phosphate reabsorption, correcting the hyperphosphataemia of hypoparathyroidism.

• PTH1 receptor on bone — High

  Continuous rather than pulsatile exposure, so the signalling favours remodelling and calcium mobilisation rather than net anabolism. Bone turnover markers rise from the abnormally low levels typical of untreated hypoparathyroidism toward normal.

• PaTHway Phase 3, randomised, double-blind, placebo-controlled with open-label extension · 26 weeks · 2023

  At 26 weeks, a composite of normal albumin-corrected serum calcium, independence from active vitamin D and therapeutic-dose calcium, and no increase in study drug dose. TransCon PTH was markedly superior to placebo; the large majority of treated patients came off conventional therapy entirely.

• PaTHway 52-week results Phase 3 open-label extension · 52 weeks · 2025

  Maintenance of normocalcaemia free of conventional therapy through 52 weeks, with continued independence from active vitamin D and therapeutic-dose calcium in the great majority of patients.

Serum calcium rises within the first days. Steady state PTH exposure takes about 7 days of daily dosing. Full independence from calcitriol and therapeutic-dose calcium typically takes several weeks of stepwise titration, and the trials assessed the composite endpoint at 26 weeks for a reason. Urinary calcium and renal parameters improve over months. Bone turnover markers, which are abnormally suppressed in untreated hypoparathyroidism, rise toward normal over the first year, and bone mineral density falls somewhat as the abnormally dense, low-turnover skeleton normalises. That fall is expected and is not a treatment failure.

The stack here is what you take away rather than what you add. Active vitamin D comes off first, then supplemental calcium tapers, and getting that order wrong is the commonest cause of hypercalcaemia in the first month. Plain vitamin D as 25-hydroxyvitamin D substrate stays. Thiazide diuretics, which many hypoparathyroid patients are on specifically to reduce hypercalciuria, usually become unnecessary and should be reviewed once urinary calcium normalises. Digoxin needs care because swinging calcium alters digoxin toxicity risk in both directions. Magnesium repletion is part of the setup rather than an afterthought. Do not combine with teriparatide or with recombinant PTH(1-84); they are the same axis.

Against conventional calcium plus calcitriol: conventional therapy is cheap and normalises serum calcium, but it does so by brute force, leaving urinary calcium high, and long-term nephrocalcinosis and chronic kidney disease are common outcomes. Palopegteriparatide is the first therapy that reliably fixes both. Against recombinant PTH(1-84), Natpara: same intent, but Natpara's 3-hour half-life meant once-daily dosing was never physiologically continuous, only about half of patients achieved the REPLACE composite endpoint, and it was withdrawn worldwide at the end of 2024 for manufacturing reasons. Yorvipath is its successor and is what former Natpara patients were moved to. Against off-label twice-daily teriparatide, which was the bridge many patients used during the Natpara withdrawal: cheaper and available, but a poor approximation of continuous replacement and it requires two injections a day.

Orphan drug pricing, plausibly in the tens of thousands of dollars per year in the US. I did not source a figure this session and will not invent one.

• ?Absolute bioavailability and plasma protein binding are not stated in the Yorvipath label.
• ?PaTHway's enrolment was not confirmed against the paper, so participants is null in both trial entries.
• ?The 4.8 L volume of distribution is quoted from the label with 50 percent variability and refers to released PTH rather than to the conjugate.
• ?Long-term renal and skeletal outcomes beyond the published extension data are genuinely unknown; this drug has been marketed for under two years.
• ?No cost figure was sourced.

• Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial Khan AA, et al., Journal of Bone and Mineral Research, 2023 · PMID 36271471

  The pivotal double-blind placebo-controlled data.

• Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial Clarke BL, et al., Journal of Clinical Endocrinology and Metabolism, 2025 · PMID 39376010

  One-year durability, which is the question that matters for a lifelong replacement therapy.

• YORVIPATH (palopegteriparatide) injection - FDA prescribing information Ascendis Pharma, DailyMed

  Source of the 4 hour median tmax, 4.8 L volume of distribution, 0.58 L/day clearance, roughly 60 hour effective half-life, 7-day steady state, the PTH(1-33) active metabolite, and the branched 40 kDa mPEG carrier with a 47.4 kDa conjugate weight.